The Hindu·2 min read·medium
Aurobindo Pharma’s generic of rheumatoid arthritis drug secures U.S. FDA nod
✦AI Summary
Aurobindo Pharma has received U.S. FDA approval for its generic version of the rheumatoid arthritis drug Tofacitinib. The company plans to launch the product immediately to compete in a market valued at approximately $494 million.
Why it matters
Impacts the pharmaceutical market by providing a lower-cost generic alternative for chronic condition treatments.
Generic drugmnaker Aurobindo Pharma has received U.S. Food and Drug Administration (U.S. FDA) final approval to manufacture and market Tofacitinib tablets, 5 mg and 10 mg.
businesshealth
Political Bias
Center
LeftLean LCenterLean RRight
Confidence: 90%
Factual reporting on corporate regulatory approval.
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in